Smokers' drug granted fast-track status
The FDA has granted fast-track status to Champix (varenicline), Pfizer's experimental smoking-cessation treatment. The company says the drug helps smokers quit by reducing the severity of cravings and withdrawal symptoms. If the review process begins in January 2006 as expected, approval to begin marketing the product could be granted by July. If approved, the drug is expected to compete with Sanofi-Aventis' Acomplia (rimonabant), which was developed originally for obesity but has been found to be effective in aiding smoking cessation as well.
Challenges for Pharmacies in 2025: What to Expect and How to Prepare
January 8th 2025Pharmacy professionals are used to overcoming obstacles in this competitive, dynamic field. But the coming year will bring challenges affecting patient care, the industry workforce and their business. Pharmacies must be ready to do more than weather the storm; they need deliberate strategy and sophisticated tools to thrive amidst these obstacles. This white paper will discuss the issues and solutions that should be at the top of every pharmacy professional’s mind as they start the new year.
